Challenges in Genetic Diagnosis of Mitochondrial Diseases: What Can Functional Genomics' Studies Do?

IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Marta Simões, Maria João Santos, Sara Martins, Maria do Carmo Macário, João Durães, Luísa Diogo, João Paulo Oliveira, José Carlos Ferreira, Manuela Grazina
{"title":"Challenges in Genetic Diagnosis of Mitochondrial Diseases: What Can Functional Genomics' Studies Do?","authors":"Marta Simões, Maria João Santos, Sara Martins, Maria do Carmo Macário, João Durães, Luísa Diogo, João Paulo Oliveira, José Carlos Ferreira, Manuela Grazina","doi":"10.2174/0118715303273290231211062420","DOIUrl":null,"url":null,"abstract":"Introduction:: Mitochondrial oxidative phosphorylation (OXPHOS) diseases are challenging both from clinical and therapeutic perspectives. The advent of next-generation sequencing (NGS) boosted the discovery of new genetic defects affecting OXPHOS, with pathogenic variants identified in >350 genes to date [1]. However, in many patients, novel variants of unknown clinical significance are found. Subsequent functional studies may clarify its pathogenic consequences and modify the variant’s classification, establishing a genetic diagnosis [2, 3]. Methods:: Analysis of data obtained from patients (P1-P5) with novel genetic causes and functional genomics’ studies performed, namely OXPHOS respiratory/glycolytic rates (Seahorse XF), enzymatic activity and assembly (BN-page), protein levels (SDS-WB), single muscle fiber assay, NGS and bioinformatics. Results/Case Report:: P1-Leigh syndrome (40y, male); Complex IV activity deficiency (full assembly absent), homozygous deletion (c.-11_13del, SURF1), not detected by NGS[2]. P2- Epileptic encephalopathy (8y, male); homozygous c.882-1G>A, FASTKD2; OXPHOS decrease; reduced FASTKD2 expression and abnormal respiratory/glycolytic rates. P3-Cardiomyopathy/ nephropathy (39y, male); c.29G>C, FASTKD2; OXPHOS decrease; reduced FASTKD2 levels. P4-CPEO (62y, female); multiple OXPHOS deficiency; mtDNA alterations (m.7486G>A, MTTS1; 4,977bp del); higher levels of mutant mtDNA alterations in COX-deficient fibers [3]. P5- Polyneuropathy (15y, female); heterozygous c.1437C>A, POLG; combined def. or normal OXPHOS activity/respiratory capacity (tissue variable), raised CI assembly; normal POLG levels. Also, proteins’ expression levels were reduced (P1-4), confirming pathogenicity. In P5, data do not support pathogenicity. Conclusion:: If specific functional results are similar to controls, one might inquire about the pathogenicity of the studied variant and more genetic or bioinformatics analyses and family investigations are needed. There are also limitations of NGS in mutation detection that Sanger sequencing can overcome (P1). When performed first, the OXPHOS activity may guide to genetic screening or interpretation, concordant to later assembly results. All cases were solved and data may be crucial for genetic counseling.","PeriodicalId":11614,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":"35 9 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118715303273290231211062420","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction:: Mitochondrial oxidative phosphorylation (OXPHOS) diseases are challenging both from clinical and therapeutic perspectives. The advent of next-generation sequencing (NGS) boosted the discovery of new genetic defects affecting OXPHOS, with pathogenic variants identified in >350 genes to date [1]. However, in many patients, novel variants of unknown clinical significance are found. Subsequent functional studies may clarify its pathogenic consequences and modify the variant’s classification, establishing a genetic diagnosis [2, 3]. Methods:: Analysis of data obtained from patients (P1-P5) with novel genetic causes and functional genomics’ studies performed, namely OXPHOS respiratory/glycolytic rates (Seahorse XF), enzymatic activity and assembly (BN-page), protein levels (SDS-WB), single muscle fiber assay, NGS and bioinformatics. Results/Case Report:: P1-Leigh syndrome (40y, male); Complex IV activity deficiency (full assembly absent), homozygous deletion (c.-11_13del, SURF1), not detected by NGS[2]. P2- Epileptic encephalopathy (8y, male); homozygous c.882-1G>A, FASTKD2; OXPHOS decrease; reduced FASTKD2 expression and abnormal respiratory/glycolytic rates. P3-Cardiomyopathy/ nephropathy (39y, male); c.29G>C, FASTKD2; OXPHOS decrease; reduced FASTKD2 levels. P4-CPEO (62y, female); multiple OXPHOS deficiency; mtDNA alterations (m.7486G>A, MTTS1; 4,977bp del); higher levels of mutant mtDNA alterations in COX-deficient fibers [3]. P5- Polyneuropathy (15y, female); heterozygous c.1437C>A, POLG; combined def. or normal OXPHOS activity/respiratory capacity (tissue variable), raised CI assembly; normal POLG levels. Also, proteins’ expression levels were reduced (P1-4), confirming pathogenicity. In P5, data do not support pathogenicity. Conclusion:: If specific functional results are similar to controls, one might inquire about the pathogenicity of the studied variant and more genetic or bioinformatics analyses and family investigations are needed. There are also limitations of NGS in mutation detection that Sanger sequencing can overcome (P1). When performed first, the OXPHOS activity may guide to genetic screening or interpretation, concordant to later assembly results. All cases were solved and data may be crucial for genetic counseling.
线粒体疾病基因诊断的挑战:功能基因组学研究能做些什么?
导言线粒体氧化磷酸化(OXPHOS)疾病在临床和治疗方面都具有挑战性。下一代测序技术(NGS)的出现促进了影响 OXPHOS 的新基因缺陷的发现,迄今已在 350 个基因中发现了致病变异[1]。然而,在许多患者中还发现了临床意义不明的新型变体。随后的功能研究可能会明确其致病后果并修改变异体的分类,从而确定基因诊断[2, 3]。方法分析新型遗传因子患者(P1-P5)的数据,并进行功能基因组学研究,即 OXPHOS 呼吸/糖酵解率(Seahorse XF)、酶活性和装配(BN-page)、蛋白质水平(SDS-WB)、单肌纤维测定、NGS 和生物信息学。结果/病例报告::P1-Leigh 综合征(40 岁,男性);复合体 IV 活性缺乏(完全组装缺失),同基因缺失(c.-11_13del,SURF1),NGS 未检测到[2]。P2-癫痫性脑病(8 岁,男性);同基因 c.882-1G>A,FASTKD2;OXPHOS 减少;FASTKD2 表达减少,呼吸/糖酵解速率异常。P3-心肌病/肾病(39 岁,男性);c.29G>C,FASTKD2;OXPHOS 减少;FASTKD2 水平降低。P4-CPEO(62 岁,女性);多种 OXPHOS 缺乏;mtDNA 改变(m.7486G>A,MTTS1;4,977bp del);COX 缺乏纤维中突变 mtDNA 改变水平较高 [3]。P5-多发性神经病(15 岁,女性);杂合子 c.1437C>A,POLG;OXPHOS 活性/呼吸能力合并缺陷或正常(组织可变),CI 组装提高;POLG 水平正常。此外,蛋白质表达水平降低(P1-4),证实了致病性。在 P5 中,数据不支持致病性。结论如果特定功能结果与对照组相似,人们可能会询问所研究变异体的致病性,需要进行更多的遗传学或生物信息学分析和家族调查。在突变检测方面,NGS 也存在桑格测序可以克服的局限性(P1)。如果先进行 OXPHOS 活动,则可指导基因筛选或解释,与后来的组装结果一致。所有病例均已解决,数据可能对遗传咨询至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Endocrine, metabolic & immune disorders drug targets
Endocrine, metabolic & immune disorders drug targets ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY
CiteScore
4.60
自引率
5.30%
发文量
217
期刊介绍: Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信